Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
NCT07070752
Type 1 Diabetes Mellitis
Chelyabinsk, Russia
View Trial DetailsNCT Number: NCT00916838
125 children with Type 1 Diabetes mellitis (T1DM) between 4 and 16 were recruited and 62 healthy siblings also enrolled in the study.
Children with T1DM and sibling controls ages 4 to 16 were assessed on memory and executive control skills at entry to the study (Test 1) and after two years of close monitoring for blood sugar events (Test 2). Diabetic children have their blood sugar tested directly before and after cognitive testing to ensure their blood sugar is within range during the testing. The 2-year follow-up period involves parents/child reporting any severe diabetic episode and periodically providing the results of the diabetic child's usual blood tests from their glucose monitoring device.
Children 7 and older also underwent high resolution MRI scans.
Looking for future studies?
Notify Me4 year–16 year
All sexes
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Washington University School of Medicine
Other
Acronym: HYPO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07070752
Type 1 Diabetes Mellitis
Chelyabinsk, Russia
View Trial DetailsNCT00879203
Cognition, Glucose Metabolism Disorders
St Louis, Missouri, United States
View Trial DetailsNCT06783309
Autoimmune Diseases, Diabetes Mellitus
Tucson, Arizona, United States
View Trial DetailsNCT07226583
Autoimmune Diseases, Behavior
Palo Alto, California, United States
View Trial Details